Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGENOVAR: ubamatamab plus carboplatin, paclitaxel, and bevacizumab in poor-response ovarian cancer
2025-524232-20-00Phase 2Authorised
- Sponsor
- Arcagy-Gineco
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ubamatamab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Arcagy-Gineco. Primary endpoints: Treatment-emergent adverse events, Dose-limiting toxicities and 2 more. Planned start Jun 2026; status: authorised.
02
Drugs
ubamatamab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2025-524232-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524232-20-00.